Navigation Links
BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
Date:7/18/2008

QUINCY, Mass., July 18 /PRNewswire/ -- BioEnergy International, LLC (BioEnergy), a privately-held, biotech-based developer and manufacturer of next-generation, renewable biochemicals and biofuels, announces the acquisition of certain assets of OmniGene Bioproducts, Inc. (OBI) and the integration of its current employees. OBI, currently based in Cambridge, MA, possesses core competencies and proprietary Bacillus host technology and metabolic pathway engineering expertise to develop efficient strains for the fermentative production of commercial products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080211/NEM085LOGO )

OBI's scientists are industry leaders with a broad range of expertise in molecular biology, cell biology, and fermentation technology, with Bacillus subtilis, Corynebacterium glutamicum, Escherichia coli, Streptomyces, and yeast species. "The addition of Jan Pero, Rog Yocum, and their world-renowned R&D team, as well as their library of proprietary strains, organisms and plasmids, represents an enormous complement to and expansion of BioEnergy's existing cutting-edge microbial platform development, said Stephen J. Gatto, Chairman and Chief Executive Officer of BioEnergy. "OBI's track record of successfully commercializing products over the years has clearly set them apart in the marketplace. We look forward to their immediate contributions toward making BioEnergy the premier industrial bioproducts player in the industry."

The OBI personnel will be incorporated into BioEnergy's existing Research & Development Group, located in Woburn, MA. "As attractive as OBI's proprietary organism portfolio is, the real strength of this transaction is the addition of this entire team's core competency and track record of metabolic pathway engineering," said Dr. Joseph Glas, Senior Vice President of BioEnergy's R&D Group. "The OBI scientists represent an immed
'/>"/>

SOURCE BioEnergy International, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock
2. Raj Khankari Named Bioenergy, Inc., CEO
3. Atlantica BioEnergy Task Force Unveiled
4. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
5. BioEnergy International Facility Opens in Bay State
6. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
7. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
8. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
9. Chindex International, Inc. Quantifies Fourth Quarter Charges
10. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
11. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... that Pierre Noel, M.D., Professor of Medicine, Mayo ... the Company’s Board of Directors. , ... are extremely fortunate to have Dr. Noel, a ... leading healthcare organization, join Entegrion’s Board. His expertise ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Thornton Cleveleys (UK) (PRWEB) March 05, 2015 ... Enhanced implantable polymer have received the CE mark (European) ... within the European Free Trade Association (EFTA) and the ... CE mark has now been granted to implants supplied ... degenerative disc spinal conditions. , Osimplant's Cervical Expandable ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2
... ST. LOUIS, Oct. 25 Sigma-Aldrich(TM) (Nasdaq:,SIAL), a ... biotechnology products to the world,s researchers, and Oxford,BioMedica ... today that,they received a key order confirming the ... BioMedica and licensed exclusively in,the research field to ...
... Study Planned, WESTMINSTER, Colo., Oct. 25 ... company focused on,the development and commercialization of small ... that results from three PDX,studies were presented as ... 2007 in San Francisco, California. The posters,described the ...
... XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB )(LSE: XTL)(TASE: XTL) ... with institutional investors relating to,a private placement of ... of,ordinary shares, represented by American Depositary Receipts (ADRs). ... Sciences Fund, Quogue,Capital LLC, SCO Capital Partners and ...
Cached Biology Technology:Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 2Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 2Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 3Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference 4XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... BEER-SHEVA, ISRAEL, May 3, 2010 Ben-Gurion University ... strain which produces large amounts of a polyunsaturated fatty ... blood cholesterol level, reducing the risk for heart attacks. ... Biotechnology Lab in the Jacob Blaustein Institutes for Desert ...
... keep the planet cool, but rising levels of carbon dioxide ... According to a new study by researchers at the Carnegie ... of the warming from increased carbon dioxide is due to ... to carbon dioxide,s better-known effect as a heat-trapping greenhouse gas. ...
... (May 3, 2010) Advances in energy conservation, better ... breakthroughs in understanding diseases: These are just a few ... be enabled by an upgrade to the Advanced Photon ... Argonne National Laboratory., DOE today announced formal approval for ...
Cached Biology News:Ben-Gurion U researchers isolate microalgal strain that could reduce cholesterol 2CO2 effects on plants increases global warming 2CO2 effects on plants increases global warming 3Upgrade to advanced photon source announced by DOE 2Upgrade to advanced photon source announced by DOE 3
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
... form: Lyophilized powder containing ... Unit Definition: One unit ... 2-phosphoglycerate to phospho(enol)pyruvate per ... 25 C. Chem comp: ...
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... mm, No. of sidearm 4 ...
Biology Products: